Dendrite Announces New Sales Force Effectiveness Solutions to Serve Global Accounts.

MORRISTOWN, N.J.--(BUSINESS WIRE)--Jan. 12, 1999--

Strategic Licensing Will Offer Tailored Products

For All Segments of Global Pharmaceutical Industry

Dendrite International, Inc. (NASDAQ/NMS:DRTE), the leading supplier of highly-specialized, enterprise-wide sales force effectiveness solutions for the Pharmaceutical and Consumer Packaged Goods (CPG) industries, today unveiled another step toward executing its new Global Reach Strategy, which will effectively expand its served market.

Through a combination of strategic acquisitions, licensing, and internal organization and development, Dendrite has positioned itself to offer complete global solutions tailored to local requirements in each segment of the pharmaceutical industry. Specifically, Dendrite has acquired an exclusive license from Marketing Management International (MMI) to market their products in Brazil.

MMI, one of the leading producers of palmtop technology products in the world, is a leading SFA supplier to emerging markets such as Latin America, Eastern Europe and the Middle East with 11,500 current users.

Dendrite earlier announced the acquisition of Associated Business Computing N.A. ("ABC") of Brussels, Belgium and the launch of the new SalesPlus division of Dendrite to provide mid-range solutions for the European and domestic markets. This solidifies Dendrite's presence to maximize clients' success in any segment of the industry, anywhere in the world.

Commenting, John Bailye, President and CEO, said, "Dendrite is further solidifying our lead with our Global Reach Strategy which answers pharmaceutical business drivers. We have said all along the increased rate of new products moving into the market and the need to hold onto existing marketshare, will become the key market drivers." Bailye added, "This, coupled with the global sales force management trends, requires mid-range and emerging companies to source the same high degree of sales force effectiveness solutions with pharmaceutical industry knowledge as major pharmaceutical companies, but in a more modular package. Dendrite, with this new licensing of MMI's products, now has the offerings to leverage mass amounts of data for the mid-range and emerging markets and create actionable information and outcome-focused results directly from their sales activity. This economically viable solution will maximize the selling capabilities for all tiers of the industry, not just the major players." The first project under this new licensing arrangement will be with Bristol-Myers Squibb Brazil.

"Dendrite's experience and presence in Brazil, combined with their service model for large sales forces, made Dendrite the best choice for MMI," said William L. White, MMI President. "Our combined results in attaining increased sales force productivity is unmatched and will provide an offering that is extremely attractive to our clients."

ABOUT DENDRITE

With a strong focus on outcomes in the Pharmaceutical and Consumer Package Goods (CPG) industries, Dendrite is a leading global provider of highly-specialized, integrated product and service offerings to support strategies for a sustained competitive advantage. Over 40,000 sales representatives and their managers in over 150 major corporations in 17 countries rely on Dendrite for a uniquely tailored combination of tools, information and skills to help them prepare for tomorrow's challenges and improve their sales success. The Company uses its highly specialized industry knowledge to develop modular software products that enhance sales force effectiveness. The products, combined with specifically tailored coaching and support services, focus sales representatives on improving their performance. With a global infrastructure as its foundation, Dendrite's commitment to unparalleled service has been the hallmark of the business and the basis of strong customer loyalty since the Company's inception.

Headquartered in Morristown, New Jersey, Dendrite employs over 750 people all around the world. For more information, visit the Company's Web site: http://www.drte.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This press release may contain statements that, if not verifiable historical fact, may be viewed as forward-looking statements that could predict future events or outcomes with respect to Dendrite and its business. The predictions embodied in these statements will involve risks and uncertainties and, accordingly, Dendrite's actual results may differ significantly from the results discussed or implied in such forward-looking statements.